<DOC>
	<DOCNO>NCT01777516</DOCNO>
	<brief_summary>This in-vitro study evaluate pharmacodynamic interaction ticagrelor active metabolite ( AR-C124910XX ) effect pharmacodynamics salicylic acid . The study consist two part in-vitro study follow ; - Part 1 : in-vitro study evaluate pharmacodynamic interaction ticagrelor active metabolite . - Part 2 : vitro study evaluate pharmacodynamic interaction ticagrelor active metabolite effect pharmacodynamics salicylic acid platelet aggregation test agonist arachidonic acid .</brief_summary>
	<brief_title>In Vitro Interaction Between Ticagrelor Its Active Metabolite Their Effects Salicylic Acid</brief_title>
	<detailed_description>This in-vitro study evaluate pharmacodynamic interaction ticagrelor active metabolite ( AR-C124910XX ) effect pharmacodynamics salicylic acid . The study consist two part in-vitro study follow ; - Part 1 : in-vitro study evaluate pharmacodynamic interaction ticagrelor active metabolite . Platelet aggregation test agonist adenosine diphosphate ( ADP ) assess in-vitro mixture blank plasma randomize paired concentration ticagrelor + AR-C124910XX . - Part 2 : vitro study evaluate pharmacodynamic interaction ticagrelor active metabolite . Platelet aggregation test agonist arachidonic acid assess in-vitro mixture blank plasma plus randomized paired concentration ticagrelor AR-C124910XX invitro mixture blank plasma ticagrelor + AR-C124910XX + salicylic acid .</detailed_description>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Salicylic Acid</mesh_term>
	<mesh_term>Salicylates</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>Subjects body weight 50 kg within 20 % ideal body weight : ideal body weight = ( height [ cm ] 100 ) *0.9 . Subjects receive understood completely information regard current study give write informed consent voluntarily participate study follow instruction specify protocol . Subjects history presence clinically significant disease . Subjects congenital acquire haematological disease . Subjects whole blood donation within last 2 month component blood donation within last month . Subject take concomitant medication include nonsteroidal antiinflammatory drug ( NASIDs ) vitamins currently within 7 day prior blood sampling .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Platelet Aggregation</keyword>
	<keyword>Cardiovascular Diseases</keyword>
	<keyword>Salicylic Acid</keyword>
</DOC>